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The article provides a brief overview of the literature on target design, exploration properties and
effectiveness of the application of recombinant baculoviruses in model systems in vivo. The results of
experiments with wild and recombinant baculoviruses are analysed in regard to the priority areas of
biomedicine such as tissue regeneration, gene therapy of cancer, development of vaccines against
infe tious diseases and malignancies.
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Intensive development of investigations and progress,
achieved in the sphere of experimental gene therapy,
are greatly conditioned by the design of efficient ways
and means of delivery of genetic material into
cultivated mammalian cells in vitro. However, the
solution of a key task of this biotechnology – efficient
delivery and expression of target gene-therapeutic
constructions into an organism – requires the
development of new vector systems with specific
properties. It is related to the fact that the process of
transport of genetically engineered constructions –
usually high molecular complexes such as
recombinant viruses or plasmid DNA – is very
complicated in an organism and mediated by both the
necessity of overcoming a number of physiological and
structural barriers and certain protection of the vectors
from the the immune system action.
Therefore, one of the most important tasks of
developing this direction in biotechnology is the
creation of the target low-toxicity transport vectors, i.e.
the main instrument of gene therapy. Here great
relevance is attributed to the necessity of delivery of
the required number of therapeutic genes or antigen
proteins into the target cells, organs, and tissues with
low-toxicity of the vector and optimal level of
expression. The primary hindrance for a wide and
efficient application of the most used vectors in gene
therapy is the induction of natural immune response to
systemic introduction of these carriers. The solution of
this problem is the creation of productive ways of
overcoming vector-mediated prolonged non-specific
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immune response, consisting in the activation of
synthesis of a number of pro-inflammatory cytokines,
maturing of antigen-presenting cells and damage of
tissues which decreases the period of transgene
expression and results in undesirable side effects.
At present many laboratories in the world perform
intensive studies aimed at the application of viral and
non-viral recombinant vectors for purposes of gene
therapy and cell engineering. Viral vectors provide a
more effective and sufficiently targeted transfer of
functional genes compared to non-viral systems. It
means the affinity of viral vectors to certain tissues (let
us say, the vectors on the basis of herpes simplex virus
are tropic to nerve tissue) and the presence of a nuclear
signal, providing a high level of expression of
introduced genes in the cell nucleus. Numerous studies
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Vector
Cloning
volume,
thousand
b.p.
Tropism
Integration into
genome
Duration of
transgene
expression
Inductio
n of
immune
respons
e
Note
Retrovirus 8 Dividing
cells
Integrates Prolonged Weak Risk of insertion
mutagenesis, low titres
Lentivirus
(Lentivirus)
8 Wide
tropism
Integrates Prolonged Weak
Risk of insertion
mutagenesis, high
efficiency of
transduction
Adenovirus
(Ad)
Up to 36 Wide
tropism
Does not
integrate
Short High Strong immunogenicity,
high titres
Adeno-associated
virus (AAV)
Less than
5
Wide
tropism
Integrates Prolonged Weak Demands adenovirus as
a helping agent, low
titres
Herpes virus
(HSV)
Up to 30 Wide
tropism
Does not
integrate
Prolonged High High titres, highly
infectious, complicated
regulation
Plasmid DNA Over 20 Wide
tropism
Depending on
DNA
construction
Up to several
months
Weak Produces easily, low
efficiency of
transduction
Nuclear
polyhedrosis
virus (NPV) of
insects
Over 30 Wide
tropism
Does not
integrate
From 3 to 60
days
Weak
High titres, cheap
scaling
Features of vectors used for target deliver of genes
support the most active application of retrovirus,
lentivirus, adenovirus, adeno-associated vectors,
demonstrating good clinical perspective. The detailed
structure of abovementioned base virus vectors and the
sphere of their application in tissue engineering and
anti-inflammatory therapy are described in the reviews
[1, 2]. However, they have some drawbacks, limiting
their further design (Table).
As seen from Table, the vectors, designed on the
basis of human viruses, have a number of considerable
shortcomings, including those related to the presence
of pre-existing antibodies with rather high toxicity [3].
This situation motivated the search for and creation of
new virus vectors that are non-pathogenic for humans
and animals. At present the most promising
baculovirus is considered to be Autographa californica
and some related baculoviruses. They interact
efficiently with different types of mammalian cells,
using penetration mechanisms, similar to those for
penetration into insect cells [4, 5]. These baculoviruses
are available for gene engineering and chemical
modification of a viral particle surface which gives a
real possibility of presenting target peptides and
proteins on it.
Nuclear polyhedrosis virus (NPV) of Lepidoptera
is among new and quite intensively elaborated virus
vectors for mammalian cells and tissues. NPV of
Autographa californica has been studied in the most
detailed way and widely used for genetic modifications
and in expression systems. The virus contains
double-stranded genome DNA, the size of
nucleocapsid varies from 40 to 50 nm in diameter and
from 200 to 400 nm in its length. Due to rather a large
number of insects that can be infected, this baculovirus
is efficiently applied as a bioinsecticide and in the
construction of highly-efficient genetic expression
systems along with other baculoviruses [6].
The baculovirus vector system is often used to
produce a considerable number of eu- and prokaryotic
proteins in the culture of insect cells. The development
of technology of modifying the baculovirus surface
allows presenting foreign peptides and even complexes
of proteins on the envelope or capsid of the virus [7].
High cloning volume of the genome of baculovirus, the
possibility of obtaining recombinant virus in high
titres, the capability of sufficiently high level of
penetration into dividing and non-dividing mammalian
cells with no replication in them, as well as low toxicity
make this vector quite a promising means for the
purposes of cell engineering and gene therapy [4].
Recombinant baculoviruses in cell therapy and
tissue engineering. Gene engineering of cells is an
important component of tissue engineering, performed
outside of the organism. Genetically modified cells are
introduced into the organism via different ways and
directly implanted into the required place. In this
respect special attention is paid to stem cells (SC) of
various origin, and first of all, to embryo stem cells
(ESC) and mesenchymal stem cells (MSC). MSC of
bone marrow, capable of differentiating in various
directions and migrating to lesions in case of
corresponding signals, attract increased attention of
scientists, working in the field of the regenerative
medicine and anti-tumour therapy.
The aim of regenerative medicine is restoration of
functions of damaged organs and tissues by
transplantation of either cells or “bio-artificial” organs
and tissues constructed outside the organism (ex vivo)
on synthetic or natural matrices. A new, intensively
developing sphere of biotechnology, which uses the
achievements of gene engineering and is an important
constituent of regenerative medicine, namely tissue
engineering, – is is aimed at overcoming the
deficiencies of traditional approaches. This is perfectly
described in the work [8] : “All procedures, restoring
lost tissues of a patient, require a specific type of
substitutional structures in the area of defect or
damage. Traditionally these appliances were
completely artificial (joints), transformed non-living
tissue (heart valves) or tissue from another place, taken
from this patient or from other patients
(transplantation). At present the clinicians have a new
available alternative – tissue engineering: replacement
of living tissues with living tissues which were
elaborated and constructed in accordance with
individual needs of each patient”
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Cell gene therapy is quite a promising strategy for
regeneration of damaged musculoskeletal tissues. Its
experimental application demonstrated high efficiency
in studies on model animals compared to the usual
approaches of osteoplasty. A good example is the
application of modified stem cells with the genes of
bone morphogenic proteins. Among the most known
and used factors of induction of bone tissue
regeneration there are bone morphogenic proteins
(BMP), some representatives of the family of growth
factors: transforming growth factor TGF-â, insulin-like
growth factor IGF, growth factor of vascular
endothelium VEGF.
Recombinant human osteoinductive bone
morphogenic protein 2 (BMP2) is widely used in the
clinical practice for restoration of damaged bone tissue.
Along with the positive results of application of
recombinant protein, a significant drawback of this
therapy, rather short lifetime of this preparation, is
revealed. The introduction of milligram amounts of the
inductor is required which is toxic for the organism.
The advantage of gene therapy is a possibility of
delivering physiological amounts of therapeutic
protein directly to the place of damage using different
vector systems. This technology allows applying much
lower doses of this factor to achieve the effect of bone
restoration, equal to that, achieved by systemic
introduction of recombinant factor.
MSC are easily transduced by virus vectors, which
allows using them for the delivery of a therapeutic
gene. It was established that proteins BMP2, BMP4,
and BMP7 initiate and support osteogenesis [9]. For
instance, BMP was shown to induce fast restoration of
large-size cranial defects in primates and rodents [10].
MSC of humans, transduced by recombinant
adenovirus, expressing BMP2, excelerate the
regeneration of femoral bones of rats [11].
Low-toxic baculovirus, non-pathogenic regarding
mammals, is a promising candidate for the work in
regenerative medicine. In vitro experiments revealed
that baculovirus A. californica is rather efficient in
transduction of articular chondrocytes of rats and
rabbits in cell cultures [12, 13]. While the recombinant
baculovirus with the marker fluorescent protein EGFP
was used in the first work, the recombinant
baculoviruses with the genes of growth factors TGF-1,
IGF-1, and BMP-2 were used in the second one. The
transduced cells were cultivated using two- or
three-dimensional matrix. The experiments revealed
that both the level of expression of growth factors by
recombinant baculovirus and the cell response to it
depend on the passage of cells and are kept on the level,
sufficient to reveal therapeutic effect. At the same time
it was noted that the expression of growth factor BMP2
by the baculovirus enhances the production of
intercellular matrix.
Further studies of the influence of growth factors
on re-differentiation of rabbit chondrocytes in the cell
culture demonstrated the enhancement of this process
in case of combined injection of two recombinant
baculoviruses with the genes of growth factors BMP2
and TGF-1 [14]. However, super transduction, i.e.
reintroduction of recombinant baculovirus, reveals
short-term dose-dependent activation of synthesis of
interferons á and â which suppresses transgene
expression to some degree [15]. Nevertheless, even in
these conditions the morphogenetic protein BMP2 is
synthesized at a sufficiently high level, thus providing
the production of intercellular matrix and increase in
differentiation of chondrocytes.
At the following stage of the development of
regenerative tissue engineering the special modified
bioreactors were used to obtain comprehensive
implants of cartilaginous tissue as a result of
transduction of chondrocytes by recombinant
baculovirus. Due to this optimization of technological
approach it was possible to create efficient implants,
restoring the hyaline structure of cartilaginous tissue
in experimental animals [16].
There are parallel studies connected with the
development of potential of MSC, genetically modified
by recombinant baculovirus, for the purposes of tissue
engineering. The capability of MSC to differentiate
into osteoblasts, chondrocytes, adipocytes, myocytes
and nervous cells under corresponding conditions
makes it quite a promising object for using in
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regenerative medicine and tissue engineering after
genetic modification [17].
High efficiency of MSC transduction by
recombinant baculovirus (up to 95%) and invariability
of their differential potential after this procedure [18]
permitted to demonstrate the induction of MSC
differentiation into osteoblasts with subsequent
regeneration of a bone defect after their transduction by
baculovirus with the gene of protein BMP2 and
transplantation into mice [19].
This work was proceeded with the purpose of
determining immunostimulatory features of MSC,
transduced ex vivo by non-recombinant baculovirus
and transplanted into animals. It was important to
estimate the availability of stem cells, transduced by
baculovirus, in the cell gene therapy. It was established
that besides local, weak response, transplantation of
SC, transduced by baculovirus, does not induce
monocytes and CD8+T cells. Therefore, an important
result of this research is the conclusion that baculovirus
induces a moderate and short-term response in MSC. It
allows foreseeing their efficient and safe modification
for gene therapy [20].
Remarkable results were obtained for reparation of
rather a large (10 mm) bone defect in rabbits.
Co-transplantation of bone marrow MSC, transduced
by two recombinant baculoviruses with the BMP2 and
VEGF genes, resulted in fast restoration of the defect in
all the experimental animals and active angiogenesis in
the damaged area [21].
A hybrid baculovirus vector was developed by the
authors on the basis of FLP/Frt-mediated
recombination with the formation of episome for
prolongation of the expression of transgene by
recombinant baculovirus. FLP/Frt is a system for
artificial homologous recombination from the
Saccharomyces cerevisiae cells. It is based on the
application of genetically engineered constructions,
containing so called “hot spots”, or sites of mitotic
recombination – Frt, and the gene of FLP-recombinase,
for which these sites are a place of revealing their
activity. The result is the formation of the episome,
where the sequence oriP/EBNA1 of Epstein-Barr virus
is used to support its replication and segregation
between daughter cells. The authors constructed two
recombinant baculoviruses – one with flp gene, and the
second– with the construction, containing oriP/EBNA1
and flanked by Frt-sequences. After transduction with
these recombinant baculoviruses a self-replicating ring
episome is formed as a result of the
excision/recombination process. The transduction of
human MSC by this hydrid vector with bmp2 gene
allows considerable prolongation of the time of
transgene expression (up to 60 days) and thus enhanced
efficiency of differentiation of bone tissue cells [22].
From the standpoint of applying MSC, transduced
by a hybrid baculovirus vector, in the clinical practice,
experimental evaluation of their biosafety is quite
important. The data on insignificant inhibition of the
MSC cells by this vector, were confirmed. It is most
likely determined by the abovementioned changes in
the expression of a number of cellular genes and the
activation of cellular immune response which
nevertheless does not affect the cell viability and
differentiation. We also confirmed the data on the
absence of both transgene integration into the genome
of MSC and change in their karyotype. We revealed no
activation of either protooncogenes or genes of tumour
suppressors. MSC, transduced by hybrid baculovirus,
do not induce the tumour formation in athymic rats.
Therefore, the abovestated data testify to the safety of
human MSC for gene therapy and availability of MSC,
genetically modified by hybrid recombinant
baculovirus, in the therapy, requiring prolonged
expression of a target gene [23]. The engineering of
mammalian cells on the basis of virus vectors,
including baculovirus, is one of the most actively
developing gene therapeutic strategies. The application
of genetically modified cells, stem cells in the first
place, allows active and targeted influence on the
processes of tissue regeneration. The usage of
recombinant baculoviruses together with target genes
of growth factors and differentiation inductors is really
promising and has considerable advantages compared
to other vectors due to their low toxicity and significant
potential of enhancing the expression of target proteins
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via gene engineering and chemical modification of the
surface of viral particles.
Experimental vaccine therapy. One of the first
references on applying the recombinant baculovirus as
an immune vector is dated 1992 [24]. As a vaccine, the
authors used both recombinant baculoviruses,
expressing genes gag and env of leukemia of cats
(FeLv), and insect cells (Sf9 line), infected by them
(notably, it is one of the first mentions of application of
insect cells, infected by recombinant baculovirus, as
vaccine). According to the authors, the experiments
were successful. However, there was no control – the
response to the introduction of non-recombinant, wild
virus in the scheme of experiment. It appeared to be a
considerable drawback of the work, as later it was
shown that the interaction of non-recombinant
baculovirusA. californicawith murine and human cells
in the culture induces the synthesis of interferons  and
, and therefore promotes antiviral defense in vivo for
infection of mice with encephalomyocarditis [25]. The
authors assumed that the induction of interferons was a
result of protein-protein interactions, mediated by a
viral fusion protein GP67 (GP64) and corresponding
cellular receptors, as antibodies to the fusion protein
inhibit the induction of interferons.
In many works the recombinant baculoviruses,
carrying the genes of different structural components
of mammalian viruses, were studied as
antigen-expressing immunovectors. The experiments
on animal models demonstrated the induction of
specific humoral immune response to the introduction1
of transducing baculoviruses with genes of
pseudorabies virus glycoprotein B (which causes acute
viral disease of the animal nervous system) [26],
hemagglutinin of influenza virus [27], glycoprotein E2
of hepatitis C virus or carcinoembrional antigen (CEA)
[28], surface-displayed protein E of Japanese
encephalitis virus [29].
Special interest of researchers is attracted to the
creation of living anti-influenza vaccines, elaboration
of injection-free ways of their administration as well as
to the technology of mass production of vaccine
preparations on the basis of recombinant
baculoviruses. A number of works showed
baculovirus-mediated induction of systemic and
mucous immune responses at intranasal and peroral
introduction which makes them promising for gene
therapy manipulations and creation of living low-toxic
immune-vector vaccines.
Different groups of researchers demonstrated on
the model systems high efficiency of anti-influenza
vaccines based on recombinant baculoviruses with the
hemagglutinin gene of avian influenza virus H5N1 [30,
31]. The advantage of vector recombinant
baculoviruses, expressing hemagglutinin and exposing
its molecules on the surface of a virus particle, is that
sparingly soluble highly hydrophobic protein is
presented at the virus display in native functional
conformation, which in its turn promotes maximal
specific immune response to the introduced antigen.
The encouraging results were obtained on a murine
model while testing peroral introduction of
recombinant baculovirus with hemagglutinin gene of
H5N1 virus using immediate early strong promoter of
white spot syndrome virus (WSSV). The result was
100% defense of mice against the lethal dose of highly
pathogenic strain of avian influenza virus which is
supported by a considerable level of specific serum
immunoglobulins and mucous immunoglobulins IgA
[32].
A high degree of mutational variability of influenza
viruses (mainly it is related to either point or
considerable modifications of amino acid sequences in
the area of antigen determinants of hemagglutinating
and neuroamidase subunits) determines the necessity
of producing vaccine preparations against ever
appearing new variants of the virus. This situation is
aggravated when it is necessary to produce large
volumes of new vaccine in a short period of time,
taking into consideration the previous varieties of
influenza virus and its functioning in the population.
Every year the influenza virus changes with the
prevalence of its other strains. Sequences of
hemagglutinin of the majority of avian influenza
viruses H5N1, circulating in recent years, fall into two
genetic groups or clades. Due to high speed of mutation
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of this virus each specific composition of the vaccine is
maximum effective for about one year. The way out of
this situation is the creation of polyvalent vaccines on
the basis of new biotechnologies. The effort to do it
using recombinant baculoviruses was reported in [33].
Having analyzed the primary structure of the main
neutralizing epitopes of hemagglutinin of different
lines of avian influenza virus, the authors selected three
vaccine strains, covering all the neutralizing epitopes
of hemagglutinin of known virus lines and exposed the
hemagglutinins selected on the surface of recombinant
baculoviruses. Thus, the polyvalent anti-influenza
vaccine was created on the basis of recombinant
baculovirus and baculophage technology. The testing
of this vaccine, performed on mice, showed its high
efficiency in the neutralization of viral infection while
using six different genetic groups as a source of
infection of avian influenza virus. At the same time
monovalent baculovirus vaccine was efficient
regarding homologous clade and two more genetically
close groups.
It is noteworthy that both baculovirus
A. californica and NPV Bombyx mori (BmNPV) were
used as vectors. Chinese researchers constructed the
recombinant virus Bmgp64HA, carrying
hemagglutinin molecule of avian influenza virus on
viral surface of the particle. The recombinant virus was
replicated in pupa of Bombyx mori, peculiar
bioreactors, and after extraction and purification it was
used in experiments with monkeys and mice. It was
shown that this virus keeps 50–67% of animals from
influenza infection depending on the dose [34].
The capability of non-recombinant baculoviruses
to induce a primary (innate) immune response at the
level of activation of pro-inflammatory cytokines
synthesis, demonstrated in the previous works, also
attracted the attention of researchers. The induction of
cellular immune response, mediated through the
activation of the synthesis of a number of cytokines,
TNF-b, IL1-b, IL1-g by the non-recombinant
baculovirus in rat hepatocytes, was shown in the early
work of authors [35].
The investigation [34] was developed in the
previously mentioned research of Japanese scientists
[27]. They revealed that introduction of both the
recombinant baculovirus, expressing hemagglutinin
gene of H1N1 influenza virus, and the baculovirus of
wild type actively prevents the development of viral
infection. At the same time it was observed that
intranasal introduction of baculovirus was the most
effective method. This observation along with the data
about the activation of murine macrophages by the
virus allowed the authors to assume possible
mechanisms of induction of antiviral immune response
by the baculovirus. The presence of mannose
monosaccharide in the structure of fusion protein of the
baculovirus GP64 results in close interaction with
mannose receptors, participating in the formation of the
immune response, on the surface of macrophages and
dendritic cells, considerably present in lymphoid
tissues of nasopharynx and lung tissues, thus inducing
the synthesis of anti-inflammatory cytokines and
antiviral response in them. Further on these authors
proved that the interaction of baculovirus and dendritic
cells of murine bone marrow enhances the expression
of such anti-inflammatory cytokines as IL12, IL16, and
IL-1â [36].
In this respect, rather interesting are the data
obtained in experiments on mice. They show] that the
activation of synthesis of interferons by baculovirus
induces both humoral and cellular immune response,
thus increasing the effect of introduced antigen.
Therefore, the baculovirus shows the features of quite
efficient adjuvant. Moreover, the authors state that
even the presence of viral particles in preparations of
recombinant proteins, obtained in baculovirus
expression system, increases their immunizing power
considerably [37]. Detailed study of the baculovirus
action as an adjuvant allowed the authors to conclude
that the viral fusion protein GP64 is most likely not a
key factor in this process, but they do not exclude the
participation of other viral components in the
mentioned mechanism.
This conclusion is supported by Abe et al. [38],
stating that the baculovirus-induced activation of the
173
BACULOVIRUS VECTORS IN EXPERIMENTAL GENE- AND VACCINE THERAPY
immune system is most likely achieved via signalling
pathway MyD88/TLR9. As the evidence, the authors
present the results of their investigations, where the
transfection of murine macrophages of RAW264.7 line
by genome baculovirus DNA activates the synthesis of
pro-inflammatory cytokine TNFá. Taking into account
that baculovirus DNA contains a significant number of
potentially active CpG-dinucleotides, and [that the]
receptors Toll-like9 actively interact with
non-methylated CpG-dinucleotides of bacterial DNA
molecules, this conclusion could have been recognized
as reasonable and logical. However, the same authors
showed later [39] that along with the participation of
Toll-like9 receptor signalling pathway in the initiation
of interferon synthesis and chemokines, activated by
them in immunocompetent cells, the induction of
interferon in the cells of embryonal fibroblasts of mice
occurs regardless of this signalling pathway and is
mediated by interferon-regulatory factors IRF7/IRF3.
The authors came to the conclusion that there might be
a system of signalling pathways of induction of cellular
adaptive and immune responses, dependent on the cell
functional specialization.
In this respect noteworthy are the data of studies,
dedicated to the response of mammalian cell genome to
the introduction of baculovirus. For instance, it was
shown that the transduction of HEK293 cells by
nuclear polyhedrosis virus of B. mori results in
considerable changing of the expression profile of
about 20 cellular genes [40]. In this case the response of
human MSC to the introduction of baculovirus AcNPV
is even more expressed and accompanied by short-term
deregulation of activity of about 800 genes, which take
part in the functioning of five cellular signalling
pathways, demonstrating the deviations in
transcriptional activity for different genes towards both
its induction and decrease. Also transient increase in
the synthesis of two cytokines – IL6 and IL8 – was
observed, and the total profile of expression of
cytokine genes is quite different from that for
specialized immune cells [41]. The authors revealed
the activation of Toll-like3 signalling pathway by
DNA-containing virus in human MSC which is rather
nonspecific for this signalling pathway, normally
induced by double-stranded viral and synthetic RNA.
The result of experiment is quite intriguing and should
be either confirmed or rejected by more detailed
investigations.
The results of previous works on different aspects
of interaction of baculoviruses with non-permissive
cells and organisms, streamlined the development of
investigations, dedicated to the improvement and
application of recombinant baculoviruses as
transducing vectors and efficient adjuvants for antigen
peptides and proteins [42, 43].
The strategy of baculovirus vector improvement
for the purposes of vaccine therapy consists in
changing the surface of a viral particle in two ways: 1)
genetic modifications of virus display for increasing
efficiency of target transport, binding and introduction
of recombinant baculovirus, protection of a viral
particle from the effect of the complement in the course
of introduction into the organism, and 2) exposing
antigenic peptides and proteins on a viral particle by
gene engineering or chemical method to increase
specific immune response in vivo [44].
The system of genetic modification of baculovirus
display, called “baculophage system”, is analogous to
the bacteriophage display system. The modification is
conducted by constructing a fused gene, including the
sequence of baculovirus gene gp64, and heterologous
protein or peptide under the control of a strong
promoter of one of later baculovirus genes – polyhedrin
gene [45–47].
A number of works were performed using genetic
modifications of viral display by the abovedescribed
method for the purposes of vaccine therapy. For
instance, [the] recombinant baculovirus, carrying
protein PbCSP of Plasmodium berghei on the viral
envelope, protected 60% of experimental mice against]
further infection [48]. This result, though good
enough,] did not satisfy the authors, and later they
constructed a baculovirus with double expression
system. The plasmodium antigen was inserted into the
genome under the cytomegaloviral expression cassette
and [was expressed on the surface of a viral particle in
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insect cells] under the baculovirus promoter of
polyhedrin gene. It enhanced specific humoral and
cellular immune response at intramuscular introduction
of immunovector [49].
The authors assumed that limited efficiency of
traditional vaccines is caused by the induction of death
of B-cells, genetic memory carriers, by plasmodium. A
new recombinant baculovirus vector, constructed by
them, presents a fragment of a surface protein PyMSP1
Plasmodium yoelii on the surface of a viral particle. At
intranasal introduction of this vector] induces not only
strong immune response, but also activates3 natural
immune response to the infection [50].
It is noteworthy that [the] recombinant baculovirus
with a double expression system was constructed and
successfully applied in earlier similar investigations
[51]. A special feature of the work was the usage of
plasmodium, causing malaria in humans, which
allowed the authors to compare the results, obtained in
vivo on mice and in vitro on human cells. In these
experiments the antigen was a surface protein CS of
sporozoites with removed C-terminal sequence for
anchor glycolipid GPI which, according to some data
[52], interferes with the expression and
immunogenicity of this protein. Out of three
constructed vectors, the most efficient one was the
baculovirus recombinant vector, combining both
expression and presentation of CS antigen on the
surface of a viral particle. This vector induces the
maturing of CS-specific CD4+- and CD8+ T-cells in
mice and activates the CS-specific CD4+- and CD8+
T-cell responses in the in vitro system quite efficiently
while using human mononuclear cells from peripheral
blood of healthy donors. The authors assumed that this
vaccine vector may be effectively used for inhibition of
hepatic stage of infection due to suppression of
sporozoites division and elimination of infected
hepatocytes.
In general, the abovementioned results of
experiments with the application of recombinant and
wild baculovirus vectors testify to their rather high
efficiency in the induction of both adaptive and
antigen-specific immune response[s].
Dendritic cells are known as highly specialized
antigen-presenting cells, performing the functions of
activation and modulation of T-cellular immune
response. The initiation of adaptive immune response
is highly dependent on the activation, functional
maturing and migration of dendritic cells. In this
respect, it is important that the interaction with
baculovirus vector induces phenotypic transformation
and functional maturing of dendritic cells, thus
increasing their ability to stimulate T-cells and
promoting the manifestation of strong adjuvant
features [53, 54].
Given in this work, though far from complete, the
list of publications presenting investigations on the
influence of both recombinant and non-modified
baculoviruses on the induction of cellular and humoral
immune response, testifies to promising future of
baculovirus application as low toxic prophylactic
vaccines.
Baculovirus vectors in experimental cancer
therapy. Due to a wide range of mammalian cells,
which could be infected by baculovirus, including
cancer cells of different origin, there is a possibility of
applying recombinant baculoviruses in gene therapy of
cancer. One of the first was the work, in which seven
different recombinant baculoviruses with the gene of
A-chain of diphtheria toxin were constructed. The most
efficient promoter was found to be a cell-specific
promoter of glial fibrillary acidic protein (GFAP) in the
expression cassette, containing the enhancer of
cytomegalovirus immediate early gene and inverted
terminal repeats of adeno-associated virus. This
combination provides a considerable increase in the
level of expression of a target gene in comparison with
low transcriptional activity of cell-specific promoter.
This recombinant baculovirus actively transduces
cancer cells and inhibits the growth of malignant brain
glioma in rats [55].
The recombinant baculovirus, expressing the gene
of telomerase-reverse rat transcriptase (TERT), was
used as an immunovector in [56]. Contrary to many
healthy tissues, the majority of malignant tumours
express TERT to some extent, due to which this
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enzyme is rather a good antigen for the induction of
anti-tumour immune response. Indeed, the splenocytes,
obtained from intramuscularly vaccinated mice,
contain increased amount of telomerase-specific
T-cells secreting IFN-ã, CD4+ predominantly. An
increased activity of natural killer cells was also
observed. The immunization of mice with this
recombinant baculovirus results in the occurrence of
anti-tumour immune response and revents them against
the development of brain tumour at subsequent
introduction of tumour cells.
In the opinion of authors of [57], the anti-tumour
immune response, induced by the wild baculovirus, is
conditioned by the activation of natural killer cells,
which is mediated by antigen-presenting dendritic
cells, transduced by baculovirus. PCR analysis showed
that this baculovirus does not infect cells NK, T and
NTK, but its genome was revealed in lymphocytes,
accumulated in spleen and liver of animals, mainly at
intravenous introduction. The model of mice,
inoculated by melanoma B16 cells, presents persuasive
proof of inhibition of metastases in liver by the virus
and high survival of experimental animals. However, it
was not clear if this anti-tumour effect is really induced
by the introduction of baculovirus of acquired
immunity proper.
To solve this question, the authors investigated the
activation of tumour-specific cytotoxic lymphocytes,
which, in the opinion of many researchers, plays an
important role in the formation of anti-tumour
response. The titre of specific antibodies was
determined in mice, injected by B16 cells into spleen,
with subsequent intravenous inoculation of
baculovirus a day later. The baculovirus-treated mice
were shown to have high level of tumour-specific
antibodies in blood serum and the specific
anti-B16-activity of cytotoxic lymphocytes was
induced [58].
The baculovirus-activated anti-tumour
mechanisms are assumed to consist in the initial
induction of specific anti-tumour activity of NK-cells
via initiation of synthesis of cytokines and NKG2D
ligands, i.e. the molecules, the expression of which is
launched at cancer transformation and infection by
viral or bacterial pathogens. The acquired immunity is
formed via induction of tumour-specific cytotoxic
lymphocytes and antibodies [58].
One of the main purposes of cancer
immunotherapy is to cause or enhance an immune
response to tumour antigens in patients. To achieve this
purpose several approaches were tested, including the
application of quite powerful antigen-presenting cells ?
dendritic cells, capable of efficient activation of
T-cells. The presentation of peptides, the derivatives of
tumour antigens on the dendritic cells surface, can
stimulate strong anti-tumour immunity. Currently one
of the new strategies in immune therapy of tumours is
the application of recombinant virus vectors, coding
tumour antigens and effectively expressing their stable
levels on the surface of dendritic cells, which, in their
turn, induce antigen-specific T-cellular response [59].
Owing to the efficient transduction of dendritic cells by
the baculovirus the latter can be used as an inductor of
anti-tumour response in the development of this
strategy. Kitajima et al., actively developing this trend,
use dendritic cells of bone marrow, transduced by the
baculovirus, in model experiments on mice with lung
carcinoma and melanoma; they demonstrated
increased survival rates of experimental animals and
considerable reduction of tumours [60].
Quite an important problem of gene therapy of
carcinogenesis is search for and application of genes,
the products of expression of which would be toxic for
tumour cells, but would not damage normal cells. One
of these genes is apoptin gene (apoptin is a small
protein, obtained from chicken anemia virus, first name
– VP3). The specificity of apoptin is inducing
apoptosis in transformed and malignant human cells
but not in normal ones [61, 62].
The application of a number of recombinant viruses
(adenovirus, parvovirus, and poxvirus), containing the
apoptin gene allowed obtaining quite promising
results, testifying to efficient anti-tumour activity of
recombinant vectors and selective effect of a target
protein, expressed by them [63]. It is quite expected
that the apoptin gene will be used for obtaining a
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recombinant baculovirus and further study of its
selective apoptotic effect on tumour cells. The
recombinant baculovirus with apoptin gene under the
promoter of cytomegalovirus efficiently induces the
apoptosis in vitro in HepG2 and H22 cells and in vivo at
intratumoral introduction in mice with
hepatocarcinoma [64]. It was also shown that the most
effective method was double introduction of the
baculovector with apoptin gene in two- week interval,
in such case the survival rate of experimental animals
increased twice compared to the control carriers of
tumour.
Quite a promising direction of gene therapy of
cancer is considered to be the application of genes,
coding suppressors of tumour growth. One of them is
gene Pdcd4. The mechanism of its action is the binding
of the product of gene expression with the factor of
translation initiation A1, which prevents RNA binding
to it. It was previously established that super
expression of mRNA of this factor occurs in human
melanoma cells [65].
Another way of increasing transduction efficiency
in experiments was a usage of folate-pegylated
recombinant baculovirus with the human gene pdcd4 –
F-P-Bac-Pdcd4. Intratumoral injection of such
baculovirus results in considerable inhibition of
tumour growth and induction of apoptosis of epithelial
carcinoma cells, caused by subcutaneous introduction
of the cell suspension of KB line (the cell line,
originating from human nasopharyngeal carcinoma,
which is a test of anti-tumour agents efficiency ) [66].
Unfortunately, the application of gene therapy
approach for inhibition of the development of cancer
tumours with various genetic constructions, involving
cytokine genes, suicidal genes or genes, inducing
apoptosis, does not guarantee maximal therapeutic
effect. As for the application of apoptotic genes, in our
opinion, principally different vector systems are
necessary, which would provide the delivery of
suicidal genes or medicinal preparations directly to
cancer cells and cause their apoptosis. Currently, the
most promising candidates for this role are stem cells
which have tropism to tumour cells and migrate to
tumour tissues. The genetically modified stem cells,
carrying therapeutic genes, may be used for the
delivery of gene products to tumours and metastases.
A promising direction in the development of
investigations in the field of gene therapy is the
elaboration of new systems of delivery of target genes
on the basis of elements of viral and non-viral vectors
and nanoparticles, which should directly migrate to
tumour cells, thus providing efficient transfer of target
genes into the main bulk of these cells and prolonged
expression of target genes without integration into their
genome.
Therefore, it seems optimal to combine gene- and
vaccine therapy to achieve maximal therapeutic effect.
The efficiency of vector vaccine therapy may be
considerably increased after overcoming the immune
suppression in cancer patients, caused by both the
presence of a large tumour and performance of
preliminary chemo- and radiotherapy. Besides, due to
heterogeneity of expression of tumour antigens in
different patients and even in different cells of tumours
and metastasis, the use of polyvalent vaccines on the
basis of recombinant vectors seems to be optimal.
Obtaining additional information about the biology
of baculoviruses and their interaction with unnatural
hosts will undoubtedly promote the construction of
highly effective recombinant vectors for their
application in clinical practice. As for the future of
recombinant baculoviruses, they most likely will be
used as immunovector vaccines due to considerable
cheapening and elaboration of modern technologies of
scaling the process of accumulation of the modified
virus and efficiency of application for preventing
infectious diseases, influenza, in the first place. Their
application as immunovaccines in treatment of cancer
depends considerably on the elaboration of new
efficient clinical protocols.
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À. Ï. Ñîëîìêî, Å. À. Çàõàðóê, Ë. È. ×àùèíà, Ë. È. Ñòðîêîâ-
ñêàÿ
Áàêóëîâèðóñíûå âåêòîðà â ýêñïåðèìåíòàïëüíîé ãåíî- è âàê-
öèíîòåðàïèè
Èíñòèòóò ìîëåêóëÿðíîé áèîëîãèè è ãåíåòèêè ÍÀÍ Óêðàèíû
Óë. Àêàäåìèêà Çàáîëîòíîãî, 150, Êèåâ, Óêðàèíà, 03680
Ðåçþìå
Ïðåäñòàâëåí êðàòêèé îáçîð äàííûõ ëèòåðàòóðû ïî öåëåâîìó
êîíñòðóèðîâàíèþ è èññëåäîâàíèþ ñâîéñòâ è ýôôåêòèâíîñòè
ïðèìåíåíèÿ â ìîäåëüíûõ ñèñòåìàõ in vivo ðåêîìáèíàíòíûõ
áàêóëîâèðóñîâ. Ïðîàíàëèçèðîâàíû ðåçóëüòàòû ýêñïåðèìåí-
òîâ ñ èñïîëüçîâàíèåì äèêèõ è ðåêîìáèíàíòíûõ áàêóëîâèðóñîâ
â òàêèõ ïðèîðèòåòíûõ îáëàñòÿõ áèîìåäèöèíû, êàê ðåãåíåðà-
öèÿ òêàíåé, ãåíîòåðàïèÿ ðàêà, ðàçðàáîòêà âàêöèí ïðîòèâ èí-
ôåêöèîííûõ çàáîëåâàíèé è çëîêà÷åñòâåííûõ
íîâîîáðàçîâàíèé.
Êëþ÷åâûå ñëîâà: áàêóëîâèðóñ, ãåíî- è èììóíîâåêòîð, ìëå-
êîïèòàþùèå, ñèñòåìà in vivo.
Î. Ï. Ñîëîìêî, Î. À. Çàõàðóê, Ë. ². ×àùèíà, Ë. ². Ñòðîêîâñüêà
Áàêóëîâ³ðóñí³ âåêòîðè â åêñïåðèìåíòàëüí³é ãåíî- òà
âàêöèíîòåðàï³¿
Ðåçþìå
Ïðåäñòàâëåíî êîðîòêèé îãëÿä äàíèõ ë³òåðàòóðè ñòîñîâíî
ö³ëüîâîãî êîíñòðóþâàííÿ ³ äîñë³äæåííÿ âëàñòèâîñòåé òà
åôåêòèâíîñò³ âèêîðèñòàíî â ìîäåëüíèõ ñèñòåìàõ in vivo ðå-
êîìá³íàíòíèõ áàêóëîâ³ðóñ³â. Ïðîàíàë³çîâàíî ðåçóëüòàòè
äîñë³ä³â ³ç çàñòîñóâàííÿì äèêèõ ³ ðåêîìá³íàíòíèõ áàêó-
ëîâ³ðóñ³â ó òàêèõ ïð³îðèòåòíèõ ãàëóçÿõ ñó÷àñíî¿ á³îìåäèöèíè,
ÿê ðåãåíåðàö³ÿ òêàíèí, ãåíîòåðàï³ÿ ðàêó, ðîçðîáêà âàêöèí
ïðîòè ³íôåêö³éíèõ çàõâîðþâàíü òà çëîÿê³ñíèõ íîâîóòâîðåíü.
Êëþ÷îâ³ ñëîâà: áàêóëîâ³ðóñ, ãåíî- òà ³ìóíîâåêòîð, ññàâö³,
ñèñòåìà in vivo.
REFERENCES
1. Zhang X., Godbey W. T. Viral vectors for gene delivery in tissue
engineering // Adv. Drug Deliv. Rev.–2006.–58, N 4.–P. 515–
534.
2. Guo Z. S., Thorne S. H., Bartlett D. L. Oncolytic virotherapy:
molecular targets in tumor-selective replication and carrier cell-
mediated delivery of oncolytic viruses // Biochim. Biophys.
Acta.–2008.–1785, N 2.–P. 217–231.
3. Nayak S., Herzog R. W. Progress and prospects: immune respon-
ses to viral vectors // Gene Ther.–2010.–17, N 3.–P. 295–304.
4. Hu Y. C. Baculoviral vectors for gene delivery: a review // Curr.
Gene. Ther.–2008.–8, N 1.–P. 54–65.
5. Solomko A. P., Zaharuk O. A., Chashchina L. I., Strokovskaya L.
I. Baculovirus integration with the vertebrate cells in system in
vitro // Biopolym. Cell.–2010.–26, N 6.–P. 441–449.
6. Luckow V. A., Summers M. D. Signals important for high-level
expression of foreign genes in Autographa californica nuclear
polyhedrosis virus expression vectors // Virology.–1988.–167,
N 1.–P. 56–71.
7. Kim Y. K., Jiang H. L., Je Y. H., Cho M. H., Cho C. S. Modifica-
tion of baculovirus for gene therapy // Commun. Curr. Res. Edu.
Topics and Trends Appl. Microbiol. / Ed. A. Mendez-Vilas.–
Badajoz, 2007.–Vol. 2.–P. 875–884.
8. Vacanti J. P., Langer R. Tissue engineering: the design and fab-
rication of living replacement devices for surgical reconstruc-
tion and transplantation // Lancet.–1999.–354, Suppl 1.–P. S32–
S34.
9. Reddi A. H. Morphogenesis and tissue engineering of bone and
cartilage: inductive signals, stem cells, and biomimetic biomate-
rials // Tissue Eng.–2000.–6, N 4.–P. 351–359.
10. Nakashima M., Reddi A. H. The application of bone morphoge-
netic proteins to dental tissue engineering // Nat. Biotechnol.–
2003.–21, N 9.–P. 1025–1032.
11. Peterson Â., Zhang J., Iglesias R., KaboM., Hedrick M., Benha-
im P., Lieberman J. R. Healing of critically sized femoral de-
fects, using genetically modified mesenchymal stem cells from
human adipose tissue // Tissue Eng.–2005.–11, N 1–2.–P. 120–
129.
12. Ho Y. C., Chen H. C., Wang K. C., Hu Y. C. Highly efficient ba-
culovirus-mediated gene transfer into rat chondrocytes // Bio-
technol. Bioeng.–2004.–88, N 5.–P. 643–651.
13. Sung L. Y., Lo W. H., Chiu H. Y., Chen H. C., Chung C. K., Lee
H. P., Hu Y. C. Modulation of chondrocyte phenotype via bacu-
lovirus-mediated growth factor expression // Biomaterials.–
2007.–28, N 23.–P. 3437–3447.
14. Sung L. Y., Chiu H. Y., Chen H. C., Chen Y. L., Chuang C. K., Hu
Y. C. Baculovirus-mediated growth factor expression in dediffe-
rentiated chondrocytes accelerates redifferentiation: effects of
combinational transduction // Tissue Eng., Part A.–2009.–15,
N 6.–P. 1353–1362.
15. Lee H. P., Matsuura Y., Chen H. C., Chen Y. L., Chuang C. K.,
Abe T., Hwang S. M., Shiah H. C., Hu Y. C. Baculovirus trans-
duction of chondrocytes elicits interferon-alpha/beta and sup-
presses transgene expression // J. Gene Med.–2009.–11, N 4.–
P. 302–312.
16. Chen H. C., Chang Y. H., Chuang C. K., Lin C. Y., Sung L. Y.,
Wang Y. H., Hu Y. C. The repair of osteochondral defects using
baculovirus-mediated gene transfer with de-differentiated chon-
drocytes in bioreactor culture // Biomaterials.–2009.–30, N 4.–
P. 674–681.
17. Kumar S., Chanda D., Ponnazhagan S. Therapeutic potential of
genetically modified mesenchymal stem cells // Gene Ther.–
2008.–15, N 10.–P. 711–715.
18. Ho Y. C., Lee H. P., Hwang S. M., Lo W. H., Chen H. C., Chung
C. K., Hu Y. C. Baculovirus transduction of human mesenchy-
mal stem cell-derived progenitor cells: variation of transgene
expression with cellular differentiation states // Gene Ther.–
2006.–13, N 20.–P. 1471–1479.
19. Chuang C. K., Sung L. Y., Hwang S. M., Lo W. H., Chen H. C.,
Hu Y. C. Baculovirus as new gene delivery vector for stem cell
engineering and bone tissue engineering // Gene Ther.–2007.–
14, N 19.–P. 1417–1424.
20. Chuang C. K., Wong T. H., Hwang S. M., Chang Y. H., Chen G.
Y., Chiu Y. C., Huang S. F., Hu Y. C. Baculovirus transduction
178
SOLOMKO A. P. ET AL
of mesenchymal stem cells: in vitro responses and in vivo immu-
ne responses after cell transplantation // Mol. Ther.–2009.–17,
N 5.–P. 889–896.
21. Lin C. Y., Chang Y. H., Lin K. J., Yen T. C., Tai C. L., Chen C. Y.,
Lo W. H., Hsiao I. T., Yu Y. C. The healing of critical-sized fe-
moral segmental bone defects in rabbits using baculovirus-en-
gineered mesenchymal stem cells // Biomaterials.–2010.–31,
N 12.–P. 3222–3230.
22. Lo W. H., Hwang S. M., Chuang C. K., Chen C. Y., Hu Y. C. De-
velopment of a hybrid baculoviral vector for sustained transgene
expression // Mol. Ther.–2009.–17, N 4.–P. 658–666.
23. Chen C. Y., Wu H. H., Chen C. P., Chern S. R., Hwang S. M.,
Huang S. F., Lo W. H., Chen G. Y., Hu Y. C. Biosafety assess-
ment of human mesenchymal stem cells engineered by hybrid
baculovirus vectors // Mol. Pharm.–2011.–Article ASAP, doi:
10.1021/mp100368d.
24. Wardley R. C., Berlinski P. J., Thomsen D. R., Meyer A. L., Post
L. E. The use of feline herpesvirus and baculovirus as vaccine
vectors for the gag and env genes of feline leukaemia virus // J.
Gen. Virol.–1992.–73, pt 7.–P. 1811–1818.
25. Gronowski A. M., Hilbert D. M., Sheehan K. C., Garotta G.,
Schreiber R. D. Baculovirus stimulates antiviral effects in mam-
malian cells // J. Virol.–1999.–73, N 12.–P. 9944–9951.
26. Aoki H., Sakoda Y., Jukuroki K., Takada A., Kida H., Fukusho
A. Induction of antibodies in mice by a recombinant baculovirus
expressing pseudorabies virus glycoprotein B in mammalian
cells // Vet. Microbiol.–1999.–68, N 3–4.–P. 197–207.
27. Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Mat-
suura Y., Takaku H. Baculovirus induces an innate immune res-
ponse and confers protection from lethal influenza virus infec-
tion in mice // J. Immunol.–2003.–171, N 3.–P. 1133–1139.
28. Facciabene A., Aurisicchio L., La Monica N. Baculovirus vec-
tors elicit antigen-specific immune responses in mice // J.
Virol.–2004.–78, N 16.–P. 8663–8672.
29. Li Y., Ye J., Cao S., Xiao S., Zhao Q., Liu X., Jin M., Chen H. Im-
munization with pseudotype baculovirus expressing envelope
protein of Japanese encephalitis virus elicits protective immuni-
ty in mice // J. Gene Med.–2009.–11, N 1.–P. 57–65.
30. Lu L., Yu L., Kwang J. Baculovirus surface-displayed hemag-
glutinin of H5N1 influenza virus sustains its authentic cleavage,
hemagglutination activity, and antigenicity // Biochem. Bio-
phys. Res. Commun.–2007.–358, N 2.–P. 404–409.
31. Wu Q., Fang L., Wu X., Li B., Luo R., Ju Z., Jin M., Chen H., Xi-
ao S. A pseudotype baculovirus-mediated vaccine confers pro-
tective immunity against lethal challenge with H5N1 avian in-
fluenza virus in mice and chickens // Mol. Immunol.–2009.–46,
N 11–12.–P. 2210–2217.
32. Prabakaran M., Madhan S., Prabhu N., Qiang J., Kwang J.
Gastrointestinal delivery of baculovirus displaying influenza vi-
rus hemagglutinin protects mice against heterologous H5N1 in-
fection // J. Virol.– 2010.–84, N 7.– P. 3201–3209.
33. Prabakaran M., He F., Meng T., Madhan S., Yunrui T., Jia Q.,
Kwang J. Neutralizing epitopes of influenza virus hemagglu-
tinin: target for the development of a universal vaccine against
H5N1 lineages // J. Virol.–2010.–84, N 22.–P.11822–11830.
34. Jin R., Lv Z., Chen Q., Quan Y., Zhang H., Li S., Chen G., Zheng Q.,
Jin L., Wu X., Chen J., Zhang Y. Safety and immunogenicity of
H5N1 influenza vaccine based on baculovirus surface display sys-
tem of Bombyx mori // PLoS One.–2008.–3, N 12.–e3933.
35. Beck N. B., Sidhu J. S., Omiecinski C. J. Baculovirus vectors re-
press phenobarbital-mediated gene induction and stimulate cy-
tokine expression in primary cultures of rat hepatocytes // Gene
Ther.–2000.–7, N 15.–P. 1274–1283.
36. Hashimoto K., Suzuki T., Sakai R., Miyazawa Y., Saito R., Ya-
mamoto H., Nakayama T., Miyano-Kurosaki N., Takaku H. In-
nate immunity activation in mouse dendritic cells infected by
baculovirus // J. Immunol.–2007.–178, suppl.–B188.
37. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculo-
virues strongly potentiate adaptive immune responses by indu-
cing type I IFN // J. Immunol.–2007.–178, N 4.–P. 2361–2369.
38. Abe T., Hemmi H., Miyamoto H., Moriishi K., Tamura S., Taka-
ku H., Akira S., Matsuura Y. Involvement of the Toll-like recep-
tor 9 signaling pathway in the induction of innate immunity by
baculovirus // J. Virol.–2005.–79, N 5.–P. 2847–2858.
39. Abe T., Kaname Y., Wen X., Tani H., Moriishi K., Uematsu S.,
Takeuchi O., Ishii K.J., Kawai T., Akira S., Matsuura Y. Baculo-
virus induces type I interferon production through Toll-like re-
ceptor-dependent and -independent pathways in a cell-type-
specific manner // J. Virol.–2009.–83, N 15.–P. 7629–7640.
40. Kenoutis C., Efrose R. C., Swevers L., Lavdas A. A., Gaitanou
M., Matsas R., Latrou K. Baculovirus-mediated gene delivery
into mammalian cells does not alter their transcriptional and
differentiating potential but is accompanied by early viral gene
expression // J. Virol.–2006.–80, N 8.–P. 4135–4146.
41.Chen G. Yu., Shiah H. C., Su H. J., Chen C. Yu., Chuang Y. J., Lo
W. H., Huang J. L., Chuang C. K., Hwang S. M., Hu Y. C.
Baculovirus transduction of mesenchymal stem cells triggers
the toll-like receptor 3 pathway // J. Virol.–2009.–83, N 20.–
P. 10548–10556.
42. Tani H., Abe T., Matsunaga T. M., Moriishi K., Matsuura Y. Ba-
culovirus vector for gene delivery and vaccine development //
Fut. Virol.–2008.–3, N 1.–P. 35–43.
43. Hu Y. C., Yao K., Wu T. Y. Baculovirus as an expression and/or
delivery vehicle for vaccine antigens // Expert Rev. Vaccines.–
2008.–7, N 3.–P. 363–371.
44. Wilson S., Baird M., Ward V. K. Delivery of vaccine peptides by
rapid conjugation to baculovirus particles // Vaccine.–2008.–
26, N 20.–P. 2451–2456.
45. Boublik Y., Di Bonito P., Jones I. M. Eukaryotic virus display:
engineering the major surface glycoprotein of the Autographa
californica nuclear polyhedrosis virus (AcNPV) for the presen-
tation of foreign proteins on the virus surface // Biotechnology.–
1995.–13, N 10.–P. 1079–1084.
46. Mottershead D., van der Linden I., von Bonsdorff C. H., Keina-
nen K., Oker-Blom C. Baculoviral display of the green fluores-
cent protein and rubella virus envelope proteins // Biochem.
Biophys. Res. Commun.–1997.–238, N 3.–P. 717–722.
47. Makela A. R., Oker-Blom C. Baculovirus display: a multifunc-
tional technology for gene delivery and eukaryotic library deve-
lopment // Adv. Virus Res.–2006.–68.–P. 91–112.
48. Yoshida S., Kondoh D., Arai E., Matsuoka H., Seki C., Tanaka
T., Okada M., Ishii A. Baculovirus virions displaying Plasmodi-
um berghei circumsporozoite protein protect mice against mala-
ria sporozoite infection // Virology.–2003.–316, N 1.–P. 161–
170.
49. Yoshida S., Kawasaki M., Hariguchi N., Hirota K., Matsumoto
M. A Baculovirus dual expression system-based malaria vacci-
ne induces strong protection against Plasmodium berghei sporo-
179
BACULOVIRUS VECTORS IN EXPERIMENTAL GENE- AND VACCINE THERAPY
zoite challenge in mice // Infect. Immun.–2009.–77, N 5.–
P. 1782–1789.
50. Yoshida S., Araki H., Yokomine T. Baculovirus-based nasal drop
vaccine confers complete protection against malaria by natural
boosting of vaccine-induced antibodies in mice // Infect. Im-
mun.–2010.–78, N 2.–P. 595–602.
51. Strauss R., Huser A., Ni S., Tuve S., Kiviat N., Sow P. S., Hof-
mann C., Lieber A. Baculovirus-based vaccination vectors al-
low for efficient induction of immune responses against Plas-
modium falciparum circumsporozoite protein // Mol. Ther.–
2007.–15, N 1.–P. 193–202.
52. Bruna-Romero O., Rocha C. D., Tsuji M., Gazzinelli R. T. En-
hanced protective immunity against malaria by vaccination with
a recombinant adenovirus encoding the circumsporozoite pro-
tein of Plasmodium lacking the GPI-anchoring motif // Vacci-
ne.–2004.–22, N 27–28.–P. 3575–3584.
53. Schutz A., Scheller N., Breinig N., Meyerhans A. The Autogra-
pha californica nuclear polyhedrosis virus AcNPV induces fun-
ctional maturation of human monocyte-derived dendritic cells //
Vaccine.–2006.–24, N 49–50.–P. 7190–7196.
54. Suzuki T., Chang M. O., Kitajima M., Takaku H. Baculovirus
activates murine dendritic cells and induces non-specific NK
cell and T cell immune responses // Cell Immunol.–2010.–262,
N 1.–P. 35–43.
55. Wang C. Y., Li F., Yang Y., Guo H. Y., Wu C. X., Wang S. Re-
combinant baculovirus containing the diphtheria toxin A gene
for malignant glioma therapy // Cancer Res.–2006.–66, N 11.–
P. 5798–5806.
56. Kim C. H., Yoon J. S., Sohn H. J., Kim C. K., Paik S. Y., Hong Y.
K., Kim T. G. Direct vaccination with pseudotype baculovirus
expressing murine telomerase induces anti-tumor immunity
comparable with RNA-electroporated dendritic cells in a muri-
ne glioma model // Cancer Lett.–2007.–250, N 2.–P. 276–283.
57. Kitajima M., Abe T., Miyano-Kurosaki N., Taniguchi M., Naka-
yama T., Takaku H. Induction of natural killer cell-dependent
antitumor immunity by the Autographa californica multiple
nuclear polyhedrosis virus // Mol. Ther.–2008.–16, N 2.–
P. 261–268.
58. Kitajima M., Takaku H. Induction of antitumor acqired immu-
nity by baculovirus Autographa californicamultiple nuclear po-
lyhedrosis virus infection in mice // Clin. Vaccine Immunol.–
2008.–15, N 2.–P. 376–378.
59. Mossoba M. E., Medin J. A. Cancer immunotherapy using viral-
ly transduced dendritic cells: animal studies and human clinical
trials // Expert. Rev. Vaccines.–2006.–5, N 5.–P. 717–732.
60. Suzuki T., Chang M. O., Kitajima M., Takaku H. Induction of
antitumor immunity against mouse carcinoma by baculovirus-
infected dendritic cells // Cell Mol. Immunol.–2010.–7, N 6.–
P. 440–446.
61. Danen-Van Oorschot A. A., Fischer D. F., Grimbergen J. M.,
Klein B., Zhuang S., Falkenburg J. H., Backendorf C., Quax P.
H., Van der Eb A. J., Noteborn M. H. Apoptin induces apoptosis
in human transformed and malignant cells but not in normal
cells // Proc. Natl Acad. Sci. USA.–1997.–94, N 11.–P. 5843–
5847.
62. Pietersen A. M., Rutjes S. A., van Tongeren J., Vogels R., Wesse-
ling J. G., Noteborn M. H. The tumor-selective viral protein
apoptin effectively kills human biliary tract cancer cells // J.
Mol. Med.–2004.–82, N 1.–P. 56–63.
63. Pietersen A. M., van der Eb M. M., Rademaker H. J., van den
Wollenberg D. J., Rabelink M. J., Kuppen P. J., van Dieren-
donck J. H., van Ormondt H., Masman D., van de Velde C. J.,
van der Eb A. J., Hoeben R. C., Noteborn M. H. Specific tumor-
cell killing with adenovirus vectors containing the apoptin gene
// Gene Ther.–1999.–6, N 5.–P. 882–892.
64. Pan Y., Fang L., Fan H., Luo R., Zhao Q., Chen H., Xiao S. Anti-
tumor effects of recombinant pseudotype baculovirus expres-
sing Apoptin in vitro and in vivo // Int. J. Cancer.–2010.–126,
N 11.–P. 2741–2751.
65. Eberle J., Krasagakis K., Orfanos C. E. Translation initiation
factor eIF-4A1 mRNA is consistently overexpressed in human
melanoma cells in vitro // Int. J. Cancer.–1997.–71, N 3.–
P. 396–401.
66. Kim Y. K., Kwon J. T., Choi J. Y., Jiang H. L., Arote R., Jere D.,
Je Y. H., Cho M. H., Cho C. S. Suppression of tumor growth in
xenograft model mice by programmed cell death 4 gene delivery
using folate-PEG-baculovirus // Cancer Gene Ther.–2010.–17,
N 11.–P. 751–760.
UDC 578.841.1:578.233
Received 21.02.10
180
SOLOMKO A. P. ET AL
